Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-01

AUTHORS

Angelo Dinota, Domenico Bilancia, Rosangela Romano, Luigi Manzione

ABSTRACT

Background: Gemcitabine and Vinorelbine both as a single agent or associated are active in advanced breast cancer patients as second line therapy, with low toxicity. In the elderly patients polichemotherapy is difficult for co-morbidity, but results with monotherapy are fewer. The use of this association as first line could be of help. Patients and methods: Thirty-four patients over 65 were treated with 1000 mg/m2 of gemcitabine and 25 mg/m2 of vinorelbine on days 1 and 8 every 21 days. An analysis of toxicities, TTP and OS were performed. Results: The ORR was 53%: a CR was obtained in five patients (15%) and a PR in 13 patients (38%). Moreover, seven patients (21%) had a stable disease maintained for 6 months. The mean duration of CR and PR were, respectively, of 10 (range 7-19) and 7 (range: 4-14), months. Toxicity was low, mainly haematological: grade 3-4 neutropenia occurred only in 7 (20%) cases without febrile neutropenia. Conclusions: The gemcitabine and vinorelbine combination shows significant activity in elderly metastatic breast cancer patients. The treatment is well tolerated and has an acceptable toxicity profile. More... »

PAGES

1-3

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10549-004-1000-1

DOI

http://dx.doi.org/10.1007/s10549-004-1000-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1026844331

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15666190


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Age Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vinblastine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vinorelbine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Oncologia Medica, Azienda Ospedaliera S. Carlo, Via Petrone 1, 85100, Potenza, Italy", 
          "id": "http://www.grid.ac/institutes/grid.416325.7", 
          "name": [
            "Medical Oncology \u201cSan Carlo\u201d Hospital, Potenza, Italy", 
            "Oncologia Medica, Azienda Ospedaliera S. Carlo, Via Petrone 1, 85100, Potenza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dinota", 
        "givenName": "Angelo", 
        "id": "sg:person.01044167051.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044167051.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology \u201cSan Carlo\u201d Hospital, Potenza, Italy", 
          "id": "http://www.grid.ac/institutes/grid.416325.7", 
          "name": [
            "Medical Oncology \u201cSan Carlo\u201d Hospital, Potenza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bilancia", 
        "givenName": "Domenico", 
        "id": "sg:person.01273011667.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273011667.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology \u201cSan Carlo\u201d Hospital, Potenza, Italy", 
          "id": "http://www.grid.ac/institutes/grid.416325.7", 
          "name": [
            "Medical Oncology \u201cSan Carlo\u201d Hospital, Potenza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Romano", 
        "givenName": "Rosangela", 
        "id": "sg:person.0756667065.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756667065.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology \u201cSan Carlo\u201d Hospital, Potenza, Italy", 
          "id": "http://www.grid.ac/institutes/grid.416325.7", 
          "name": [
            "Medical Oncology \u201cSan Carlo\u201d Hospital, Potenza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Manzione", 
        "givenName": "Luigi", 
        "id": "sg:person.01260533117.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260533117.65"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1006136112585", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040715403", 
          "https://doi.org/10.1023/a:1006136112585"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-01", 
    "datePublishedReg": "2005-01-01", 
    "description": "Background: Gemcitabine and Vinorelbine both as a single agent or associated are active in advanced breast cancer patients as second line therapy, with low toxicity. In the elderly patients polichemotherapy is difficult for co-morbidity, but results with monotherapy are fewer. The use of this association as first line could be of help. Patients and methods: Thirty-four patients over 65 were treated with 1000 mg/m2 of gemcitabine and 25 mg/m2 of vinorelbine on days 1 and 8 every 21 days. An analysis of toxicities, TTP and OS were performed. Results: The ORR was 53%: a CR was obtained in five patients (15%) and a PR in 13 patients (38%). Moreover, seven patients (21%) had a stable disease maintained for 6 months. The mean duration of CR and PR were, respectively, of 10 (range 7-19) and 7 (range: 4-14), months. Toxicity was low, mainly haematological: grade 3-4 neutropenia occurred only in 7 (20%) cases without febrile neutropenia. Conclusions: The gemcitabine and vinorelbine combination shows significant activity in elderly metastatic breast cancer patients. The treatment is well tolerated and has an acceptable toxicity profile.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10549-004-1000-1", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "89"
      }
    ], 
    "keywords": [
      "breast cancer patients", 
      "line therapy", 
      "cancer patients", 
      "elderly metastatic breast cancer patients", 
      "advanced breast cancer patients", 
      "metastatic breast cancer patients", 
      "m2 of gemcitabine", 
      "m2 of vinorelbine", 
      "second line therapy", 
      "acceptable toxicity profile", 
      "first line therapy", 
      "advanced breast cancer", 
      "biweekly administration", 
      "stable disease", 
      "febrile neutropenia", 
      "vinorelbine combination", 
      "mean duration", 
      "grade 3", 
      "breast cancer", 
      "day 1", 
      "toxicity profile", 
      "analysis of toxicity", 
      "patients", 
      "single agent", 
      "gemcitabine", 
      "vinorelbine", 
      "first line", 
      "neutropenia", 
      "therapy", 
      "months", 
      "toxicity", 
      "significant activity", 
      "polichemotherapy", 
      "monotherapy", 
      "low toxicity", 
      "cancer", 
      "disease", 
      "administration", 
      "TTP", 
      "treatment", 
      "duration", 
      "association", 
      "m2", 
      "days", 
      "agents", 
      "OS", 
      "PR", 
      "activity", 
      "cases", 
      "profile", 
      "use", 
      "combination", 
      "lines", 
      "results", 
      "analysis", 
      "Cr", 
      "help", 
      "ORR", 
      "method", 
      "elderly patients polichemotherapy", 
      "patients polichemotherapy", 
      "elderly advanced breast cancer"
    ], 
    "name": "Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer", 
    "pagination": "1-3", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1026844331"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10549-004-1000-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15666190"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10549-004-1000-1", 
      "https://app.dimensions.ai/details/publication/pub.1026844331"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_410.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10549-004-1000-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-004-1000-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-004-1000-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-004-1000-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-004-1000-1'


 

This table displays all metadata directly associated to this object as RDF triples.

199 TRIPLES      22 PREDICATES      102 URIs      93 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10549-004-1000-1 schema:about N015268d78d10428b9ede5c286c46f553
2 N178851bd8ae14cc89ae316c0b32b0b70
3 N2f6ee11b236f4bcaa0cbaa293f2726e6
4 N899e02108ed9444fbd0fb1e8dc8d379a
5 N8f597085053648d59c169db33af90efc
6 N9557b29d635141c9b2d1d8d95c930b96
7 N9ec93f9037d145aa9d61b49434435877
8 Na76b5383f6394625967c5a68aa26b499
9 Nabb931b3f4be4befb06ec154ea00935e
10 Nc993945c3d6e4773a68d9d6f2be24982
11 Ndd84716983ef4fdf939227a7c1e725d4
12 Nf56b0f93671644918bbeeba6b331d469
13 anzsrc-for:11
14 anzsrc-for:1112
15 schema:author N00c06a6d31074eb1815258756dfbb02c
16 schema:citation sg:pub.10.1023/a:1006136112585
17 schema:datePublished 2005-01
18 schema:datePublishedReg 2005-01-01
19 schema:description Background: Gemcitabine and Vinorelbine both as a single agent or associated are active in advanced breast cancer patients as second line therapy, with low toxicity. In the elderly patients polichemotherapy is difficult for co-morbidity, but results with monotherapy are fewer. The use of this association as first line could be of help. Patients and methods: Thirty-four patients over 65 were treated with 1000 mg/m2 of gemcitabine and 25 mg/m2 of vinorelbine on days 1 and 8 every 21 days. An analysis of toxicities, TTP and OS were performed. Results: The ORR was 53%: a CR was obtained in five patients (15%) and a PR in 13 patients (38%). Moreover, seven patients (21%) had a stable disease maintained for 6 months. The mean duration of CR and PR were, respectively, of 10 (range 7-19) and 7 (range: 4-14), months. Toxicity was low, mainly haematological: grade 3-4 neutropenia occurred only in 7 (20%) cases without febrile neutropenia. Conclusions: The gemcitabine and vinorelbine combination shows significant activity in elderly metastatic breast cancer patients. The treatment is well tolerated and has an acceptable toxicity profile.
20 schema:genre article
21 schema:inLanguage en
22 schema:isAccessibleForFree false
23 schema:isPartOf N1d8b0c54f3044c23adc1fe82cc713dc4
24 N3829834fac7c471bb873cd7d01e695fc
25 sg:journal.1092777
26 schema:keywords Cr
27 ORR
28 OS
29 PR
30 TTP
31 acceptable toxicity profile
32 activity
33 administration
34 advanced breast cancer
35 advanced breast cancer patients
36 agents
37 analysis
38 analysis of toxicity
39 association
40 biweekly administration
41 breast cancer
42 breast cancer patients
43 cancer
44 cancer patients
45 cases
46 combination
47 day 1
48 days
49 disease
50 duration
51 elderly advanced breast cancer
52 elderly metastatic breast cancer patients
53 elderly patients polichemotherapy
54 febrile neutropenia
55 first line
56 first line therapy
57 gemcitabine
58 grade 3
59 help
60 line therapy
61 lines
62 low toxicity
63 m2
64 m2 of gemcitabine
65 m2 of vinorelbine
66 mean duration
67 metastatic breast cancer patients
68 method
69 monotherapy
70 months
71 neutropenia
72 patients
73 patients polichemotherapy
74 polichemotherapy
75 profile
76 results
77 second line therapy
78 significant activity
79 single agent
80 stable disease
81 therapy
82 toxicity
83 toxicity profile
84 treatment
85 use
86 vinorelbine
87 vinorelbine combination
88 schema:name Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer
89 schema:pagination 1-3
90 schema:productId N378c869b41b94916aa9202c567dd1d8c
91 N94acbb0f52244d0e889b9d34f42e94e1
92 Nc9d4db94805f4e909ebd6b744c0f4caf
93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026844331
94 https://doi.org/10.1007/s10549-004-1000-1
95 schema:sdDatePublished 2021-11-01T18:08
96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
97 schema:sdPublisher Nc6b7533efcf741a19d6840ee93219bc1
98 schema:url https://doi.org/10.1007/s10549-004-1000-1
99 sgo:license sg:explorer/license/
100 sgo:sdDataset articles
101 rdf:type schema:ScholarlyArticle
102 N00c06a6d31074eb1815258756dfbb02c rdf:first sg:person.01044167051.02
103 rdf:rest Ned6e5253ed324c3cbb6ecc1e6bf7ee3e
104 N015268d78d10428b9ede5c286c46f553 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Quality of Life
106 rdf:type schema:DefinedTerm
107 N178851bd8ae14cc89ae316c0b32b0b70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Deoxycytidine
109 rdf:type schema:DefinedTerm
110 N1d8b0c54f3044c23adc1fe82cc713dc4 schema:issueNumber 1
111 rdf:type schema:PublicationIssue
112 N2f6ee11b236f4bcaa0cbaa293f2726e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Humans
114 rdf:type schema:DefinedTerm
115 N378c869b41b94916aa9202c567dd1d8c schema:name pubmed_id
116 schema:value 15666190
117 rdf:type schema:PropertyValue
118 N3829834fac7c471bb873cd7d01e695fc schema:volumeNumber 89
119 rdf:type schema:PublicationVolume
120 N880ae443c6a74dbe806ba65ef32113b1 rdf:first sg:person.0756667065.47
121 rdf:rest N8cd30199d1b94bb7af6feb6c4916b387
122 N899e02108ed9444fbd0fb1e8dc8d379a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Vinblastine
124 rdf:type schema:DefinedTerm
125 N8cd30199d1b94bb7af6feb6c4916b387 rdf:first sg:person.01260533117.65
126 rdf:rest rdf:nil
127 N8f597085053648d59c169db33af90efc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Aged
129 rdf:type schema:DefinedTerm
130 N94acbb0f52244d0e889b9d34f42e94e1 schema:name dimensions_id
131 schema:value pub.1026844331
132 rdf:type schema:PropertyValue
133 N9557b29d635141c9b2d1d8d95c930b96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Disease Progression
135 rdf:type schema:DefinedTerm
136 N9ec93f9037d145aa9d61b49434435877 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Breast Neoplasms
138 rdf:type schema:DefinedTerm
139 Na76b5383f6394625967c5a68aa26b499 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Aged, 80 and over
141 rdf:type schema:DefinedTerm
142 Nabb931b3f4be4befb06ec154ea00935e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Female
144 rdf:type schema:DefinedTerm
145 Nc6b7533efcf741a19d6840ee93219bc1 schema:name Springer Nature - SN SciGraph project
146 rdf:type schema:Organization
147 Nc993945c3d6e4773a68d9d6f2be24982 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Antineoplastic Combined Chemotherapy Protocols
149 rdf:type schema:DefinedTerm
150 Nc9d4db94805f4e909ebd6b744c0f4caf schema:name doi
151 schema:value 10.1007/s10549-004-1000-1
152 rdf:type schema:PropertyValue
153 Ndd84716983ef4fdf939227a7c1e725d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Vinorelbine
155 rdf:type schema:DefinedTerm
156 Ned6e5253ed324c3cbb6ecc1e6bf7ee3e rdf:first sg:person.01273011667.65
157 rdf:rest N880ae443c6a74dbe806ba65ef32113b1
158 Nf56b0f93671644918bbeeba6b331d469 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Age Factors
160 rdf:type schema:DefinedTerm
161 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
162 schema:name Medical and Health Sciences
163 rdf:type schema:DefinedTerm
164 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
165 schema:name Oncology and Carcinogenesis
166 rdf:type schema:DefinedTerm
167 sg:journal.1092777 schema:issn 0167-6806
168 1573-7217
169 schema:name Breast Cancer Research and Treatment
170 schema:publisher Springer Nature
171 rdf:type schema:Periodical
172 sg:person.01044167051.02 schema:affiliation grid-institutes:grid.416325.7
173 schema:familyName Dinota
174 schema:givenName Angelo
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044167051.02
176 rdf:type schema:Person
177 sg:person.01260533117.65 schema:affiliation grid-institutes:grid.416325.7
178 schema:familyName Manzione
179 schema:givenName Luigi
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01260533117.65
181 rdf:type schema:Person
182 sg:person.01273011667.65 schema:affiliation grid-institutes:grid.416325.7
183 schema:familyName Bilancia
184 schema:givenName Domenico
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273011667.65
186 rdf:type schema:Person
187 sg:person.0756667065.47 schema:affiliation grid-institutes:grid.416325.7
188 schema:familyName Romano
189 schema:givenName Rosangela
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756667065.47
191 rdf:type schema:Person
192 sg:pub.10.1023/a:1006136112585 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040715403
193 https://doi.org/10.1023/a:1006136112585
194 rdf:type schema:CreativeWork
195 grid-institutes:grid.416325.7 schema:alternateName Medical Oncology “San Carlo” Hospital, Potenza, Italy
196 Oncologia Medica, Azienda Ospedaliera S. Carlo, Via Petrone 1, 85100, Potenza, Italy
197 schema:name Medical Oncology “San Carlo” Hospital, Potenza, Italy
198 Oncologia Medica, Azienda Ospedaliera S. Carlo, Via Petrone 1, 85100, Potenza, Italy
199 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...